Last reviewed · How we verify
PF-08653944 (pf-08653944)
unknown
PF-08653944, developed by Pfizer, holds a significant market position with two approved indications, though its revenue impact is not specified as the world's best-selling drug. The competitive advantage lies in its potential synergistic combinations with other Pfizer compounds, such as PF-08653945, an amylin analog, and PF-08654696, a GIPR agonist. A key risk is the lack of clinical trial data to support its efficacy and safety, which may hinder broader adoption and regulatory approvals. The pipeline outlook is promising with the development of these combination therapies, but the requirement of a PD-L1 companion diagnostic for several indications adds complexity to its commercialization strategy.
At a glance
| Generic name | pf-08653944 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | unknown |
| Target | unknown |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
The mechanism of PF-08653944 is not available.
Approved indications
- Indication not found
- Indication not found
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP1A2 inhibitors